| Name | Title | Contact Details |
|---|
Arkeyo offers self-service coin counting / cash dispensing kiosks to banks, casinos, grocery stores and other retail locations. Arkeyo is delivering high profile products and services designed to engage and efficiently monetize the growing need for a new self-service coin alternative in the USA and Europe. Clients can select from a full set of product lines, in their own language and their own currency. Arkeyo also picks up and processes coin bins and coin bags. Unlike legacy self-service coin offerings, Arkeyo gives retailers powerful tools to narrowcast their direct marketing, to identify and engage the right customer with the right offering at the right time, enhancing results and efficiency. Rules-based intelligence, routing and reporting tools offer retailers the opportunity to increase sales, lower customer service costs, shorten ‘float time and encourage repeat business. Through an affiliate program, users of the self-service coin machines can earn credit toward future purchases and exchange points with offline affiliate partners.
Cimplifi is a leading integrated legal services provider, leveraging technology and expertise to simplify the experience of eDiscovery and contract analytics for law firms and legal departments. Our client-centric ecosystem and experience offer a curated portfolio of technology-enabled solutions that integrates proprietary tools and automated workflows with market-leading software to deliver an easy-to-use, end-to-end system that streamlines processes, unifies reporting, and empowers users. For more than two decades, clients have relied on our expertise and ingenuity to solve complex challenges, bring innovative solutions, and deliver intelligence and insight to help them manage risk, control costs, and get more done, more effectively and with far less effort and stress. Cimplifi is ISO 27001 certified and is a division of System One. Learn more at www.cimplifi.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
LFI specializes in the sale and service of contemporary furnishings to public, private, school, and academic libraries. By meeting the rapidly changing sociological and technological changes through design and product, LFI has become the Midwests leading library furnishing company.